Please login to the form below

Not currently logged in
Email:
Password:

drug safety

This page shows the latest drug safety news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s upadacitinib aces phase III trial

AbbVie’s upadacitinib aces phase III trial

AbbVie’ s upadacitinib aces phase III trial. Arthritis drug outperformed both placebo and Humira in the study. ... s drug fared much better compared to its active comparator on the tougher ACR50 and ACR70 measures.

Latest news

  • Boehringer adds to pipeline again with €628m Autifony CNS deal Boehringer adds to pipeline again with €628m Autifony CNS deal

    Boehringer adds to pipeline again with 628m Autifony CNS deal. Bags rights to the GlaxoSmithKline spin-out's small-molecule drug for schizophrenia. ... The drug is being tested in two studies, one involving healthy volunteers challenged with ketamine and

  • Ablynx buoyant as lead antibody aces phase III trial Ablynx buoyant as lead antibody aces phase III trial

    Another secondary measure showed that the drug also reduced the chances of aTTP recurrence by 67%, and the results also backed up the safety profile of the drug, with the only ... Analysts at Jefferies said the data were as good as could be hoped for,

  • FDA wants more data on J&J’s arthritis drug Plivensia FDA wants more data on J&J’s arthritis drug Plivensia

    FDA wants more data on J&J’ s arthritis drug Plivensia. Requests further evidence on the drug’s safety profile after patient deaths link. ... safety after its advisors highlighted a higher of number deaths in patients treated with the drug rather

  • Sandoz says Humira biosimilar clears clinical hurdle Sandoz says Humira biosimilar clears clinical hurdle

    Sandoz says Humira biosimilar clears clinical hurdle. Its drug matches the safety and efficacy of AbbVie’s plaque psoriasis blockbuster. ... The new data - from a 51-week study which shows that Sandoz' drug matched the safety and efficacy of Humira

  • Lilly planning early re-file for JAK inhibitor baricitinib Lilly planning early re-file for JAK inhibitor baricitinib

    The FDA also had concerns about Xeljanz's safety at higher doses, approving Pfizer's drug at a 5mg twice-daily dose only, saying the benefits of the higher 10mg dose ... did not outweigh its risks, although the company insists it has seen no evidence of

More from news
Approximately 4 fully matching, plus 451 partially matching documents found.

Latest Intelligence

  • A new era of smart pharma A new era of smart pharma

    Blending Reportum with AI and Robotic tools affords pharma companies the opportunity to transform their end-to-end drug safety processes today. ... Medical adherence is being improved. Drug delivery technology has improved significantly in recent years.

  • Drug safety

    Healthcare terms - Drug safety.

  • Healthcare Glossary

    Search and browse hundreds of industry specific terms and phrases or suggest your own terms and definitions. Asymptomatic. Showing no signs of a disease or infection.

  • The gold standard of scientific evidence The gold standard of scientific evidence

    Dr Basu supports using phase II clinical trials to determine drug safety and then replacing phase III clinical trials with only-in-research (OIR) labelling over a specified period (eg, two ... The FDA uses RWE to monitor drug safety as part of the

  • AI’s potential in the pharma life cycle AI’s potential in the pharma life cycle

    having. There is also important safety monitoring potential and drug feedback potential, as long as intelligent tools based on AI and machine learning are in the background offering companies what to ... possible, all of which could have a bearing on

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

  • 21st Century Cures Act: a commercial perspective on how the new FDA regulation could revolutionise use of RWE and analytics in healthcare

    It brings numerous changes to the US drug development landscape, impacting patients, academia, research institutions, and industry. ... For years, the priorities of drug development programmes were to prove the safety and efficacy of a drug in a placebo

  • "Legal highs" ruling leaves illegal labs laughing

    Drug abuse is a massive medical and social problem in the UK, and it has been compounded by the availability of new psychoactive agents virtually everywhere. ... The recent court case leaves the issue in limbo, but it may also present an opportunity to

  • Pure Drug Safety Limited

    Pure Drug Safety Limited. We are a leading global pharmacovigilance provider offering detailed responsive solutions through strategic thinking to help 'Pharma make sense of Drug Safety'. ... Pure Drug Safety Limited.

  • Meet Recruitment

    We recruit professionals into Global Pharma, Biotech and CRO's, across Clinical Operations, Drug Safety, Medical, Data, Regulatory, Pharmaceutical Marketing, Healthcare Advertising, Medical Communications, PR and Digital, across client service,

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics